Safety and efficacy of belimumab to treat systemic lupus erythematosus in academic clinical practices

Journal of Rheumatology

Volumn 42, Issue 12, 2015, Pages 2288-2295

  Hui Yuen, Joyce S ^a   Reddy, Arthi ^b   Taylor, Jennifer ^a   Li, Xiaoqing ^a   Eichenfield, Andrew H ^a   Bermudez, Liza M ^a   Starr, Amy J ^a   Imundo, Lisa F ^a   Buyon, Jill ^b   Furie, Richard A ^c   Kamen, Diane L ^d   Manzi, Susan ^e   Petri, Michelle ^f   Ramsey Goldman, Rosalind ^g   Van Vollenhoven, Ronald F ^h   Wallace, Daniel J ⁱ   Askanase, Anca ^a  

^a NewYork Presbyterian Hospital   (United States)

^b NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^c DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

^d MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^e TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g NORTHWESTERN UNIVERSITY   (United States)

^h KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

ⁱ CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

Belimumab; Childhood onset SLE; SLE treatment; Systemic lupus erythematosus

Indexed keywords

ANTIMALARIAL AGENT; BELIMUMAB; COMPLEMENT COMPONENT C3; CORTICOSTEROID; DOUBLE STRANDED DNA ANTIBODY; IMMUNOSUPPRESSIVE AGENT; PREDNISONE; MONOCLONAL ANTIBODY;

ADOLESCENT; ADULT; AFRICAN AMERICAN; AGED; ARTHRITIS; ARTICLE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; DEPRESSION; DISEASE EXACERBATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; ETHNIC DIFFERENCE; FEMALE; GROUP A STREPTOCOCCAL INFECTION; HEART INFARCTION; HUMAN; INFECTION; INFLAMMATION; INFUSION RELATED REACTION; LUPUS ERYTHEMATOSUS NEPHRITIS; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MULTICENTER STUDY; MYOSITIS; OBSERVATIONAL STUDY; PNEUMONIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEINURIA; PSYCHOSIS; RACE DIFFERENCE; RASH; SEIZURE; SYSTEMIC LUPUS ERYTHEMATOSUS; UNITED STATES; UNIVERSITY HOSPITAL; AGE; DOSE RESPONSE; DRUG ADMINISTRATION; FOLLOW UP; LUPUS ERYTHEMATOSUS, SYSTEMIC; MIDDLE AGED; ONSET AGE; PATIENT SAFETY; QUESTIONNAIRE; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SEX DIFFERENCE; TIME FACTOR; TREATMENT OUTCOME; YOUNG ADULT;

ACADEMIC MEDICAL CENTERS; ADOLESCENT; ADULT; AGE FACTORS; AGE OF ONSET; ANTIBODIES, MONOCLONAL, HUMANIZED; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; PATIENT SAFETY; PROSPECTIVE STUDIES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SEX FACTORS; SURVEYS AND QUESTIONNAIRES; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84948799807     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.150470     Document Type: Article

References (31)

1. Askanase A, Shum K, Mitnick H. Systemic lupus erythematosus: an overview. Soc Work Health Care 2012;51:576-86.
2. Xiong W, Lahita RG. Pragmatic approaches to therapy for systemic lupus erythematosus. Nat Rev Rheumatol 2014;10:97-107.
3. Parodis I, Axelsson M, Gunnarsson I. Belimumab for systemic lupus erythematosus: a practice-based view. Lupus 2013;22:372-80.
4. Cancro MP, D'Cruz DP, Khamashta MA. The role of B lymphocyte stimulator (BLyS) in systemic lupus erythematosus. J Clin Invest 2009;119:1066-73.
5. Zhang J, Roschke V, Baker KP, Wang Z, Alarcon GS, Fessler BJ, et al. Cutting edge: a role for B lymphocyte stimulator in systemic lupus erythematosus. J Immunol 2001;166:6-10.
6. Petri M, Stohl W, Chatham W, McCune WJ, Chevrier M, Ryel J, et al. Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus. Arthritis Rheum 2008;58:2453-9.
7. Navarra SV, Guzman RM, Gallacher AE, Hall S, Levy RA, Jimenez RE, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet 2011;377:721-31.
8. Furie R, Petri M, Zamani O, Cervera R, Wallace DJ, Tegzova D, et al. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum 2011;63:3918-30.
9. Mina R, Brunner HI. Pediatric lupus-are there differences in presentation, genetics, response to therapy, and damage accrual compared with adult lupus? Rheum Dis Clin North Am 2010; 36:53-80, vii-viii.
10. Font J, Cervera R, Espinosa G, Pallares L, Ramos-Casals M, Jimenez S, et al. Systemic lupus erythematosus (SLE) in childhood: analysis of clinical and immunological findings in 34 patients and comparison with SLE characteristics in adults. Ann Rheum Dis 1998;57:456-9.
11. Brunner HI, Gladman DD, Ibanez D, Urowitz MD, Silverman ED. Difference in disease features between childhood-onset and adult-onset systemic lupus erythematosus. Arthritis Rheum 2008;58:556-62.
12. Hersh AO, von Scheven E, Yazdany J, Panopalis P, Trupin L, Julian L, et al. Differences in long-term disease activity and treatment of adult patients with childhood- and adult-onset systemic lupus erythematosus. Arthritis Rheum 2009;61:13-20.
13. Ramírez Gómez LA, Uribe Uribe O, Osio Uribe O, Grisales Romero H, Cardiel MH, Wojdyla D, et al. Childhood systemic lupus erythematosus in Latin America. The GLADEL experience in 230 children. Lupus 2008;17:596-604.
14. Tucker LB, Menon S, Schaller JG, Isenberg DA. Adult- and childhood-onset systemic lupus erythematosus: a comparison of onset, clinical features, serology, and outcome. Br J Rheumatol 1995;34:866-72.
15. Tucker LB, Uribe AG, Fernandez M, Vila LM, McGwin G, Apte M, et al. Adolescent onset of lupus results in more aggressive disease and worse outcomes: results of a nested matched case-control study within LUMINA, a multiethnic US cohort (LUMINA LVII). Lupus 2008;17:314-22.
16. Hui-Yuen JS, Imundo LF, Avitabile C, Kahn PJ, Eichenfield AH, Levy DM. Early versus later onset childhood-onset systemic lupus erythematosus: clinical features, treatment and outcome. Lupus 2011;20:952-9.
17. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997;40:1725.
18. Petri M, Orbai AM, Alarcon GS, Gordon C, Merrill JT, Fortin PR, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 2012;64:2677-86.
19. Petri M, Barr SG, Buyon J, Davis J, Ginzler E, Kalunian K. RIFLE: Responder Index for Lupus Erythematosus [abstract]. Arthritis Rheum Suppl 2000;43 Suppl:S244.
20. Yee CS, Farewell V, Isenberg DA, Griffiths B, Teh LS, Bruce IN, et al. The BILAG-2004 index is sensitive to change for assessment of SLE disease activity. Rheumatology 2009;48:691-5.
21. Mosca M, van Vollenhoven R. New drugs in systemic lupus erythematosus: when to start and when to stop. Clin Exp Rheumatol Suppl 2013;31 Suppl 78:S82-5.
22. Furie RA, Petri MA, Wallace DJ, Ginzler EM, Merrill JT, Stohl W, et al. Novel evidence-based systemic lupus erythematosus responder index. Arthritis Rheum 2009;61:1143-51.
23. Touma Z, Gladman DD, Ibanez D, Urowitz MB. Development and initial validation of the systemic lupus erythematosus disease activity index 2000 responder index 50. J Rheumatol 2011; 38:275-84.
24. Touma Z, Gladman DD, Ibanez D, Taghavi-Zadeh S, Urowitz MB. Systemic Lupus Erythematosus Disease Activity Index 2000 Responder Index-50 enhances the ability of SLE Responder Index to identify responders in clinical trials. J Rheumatol 2011; 38:2395-9.
25. Askanase AD, Yazdany J, Molta CT. Post-marketing experiences with belimumab in the treatment of SLE patients. Rheum Dis Clin North Am 2014;40:507-17, viii.
26. van Vollenhoven RF, Petri MA, Cervera R, Roth DA, Ji BN, Kleoudis CS, et al. Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response. Ann Rheum Dis 2012;71:1343-9.
27. Chakravarty EF, Bush TM, Manzi S, Clarke AE, Ward MM. Prevalence of adult systemic lupus erythematosus in California and Pennsylvania in 2000: estimates obtained using hospitalization data. Arthritis Rheum 2007;56:2092-4.
28. Pineles D, Valente A, Warren B, Peterson MG, Lehman TJ, Moorthy LN. Worldwide incidence and prevalence of pediatric onset systemic lupus erythematosus. Lupus 2011;20:1187-92.
29. Ginzler EM, Wallace DJ, Merrill JT, Furie RA, Stohl W, Chatham WW, et al. Disease control and safety of belimumab plus standard therapy over 7 years in patients with systemic lupus erythematosus. J Rheumatol 2014;41:300-9.
30. Wallace DJ, Navarra S, Petri MA, Gallacher A, Thomas M, Furie R, et al. Safety profile of belimumab: pooled data from placebo-controlled phase 2 and 3 studies in patients with systemic lupus erythematosus. Lupus 2013;22:144-54.
31. Dooley MA, Houssiau F, Aranow C, D'Cruz DP, Askanase A, Roth DA, et al. Effect of belimumab treatment on renal outcomes: results from the phase III belimumab clinical trials in patients with SLE. Lupus 2013;22:63-72.